The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.
Open accessAbstract
BACKGROUND: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors are widely prescribed for hyperlipidemia, yet their effect on the evolution of coronary atherosclerosis has not been defined. METHODS AND RESULTS: To address this issue, 331 patients with diffuse but not necessarily severe coronary atherosclerosis documented on a recent arteriogram and with fasting serum cholesterol between 220 and 300 mg/dL were enrolled in a randomized, double-blind, placebo-controlled trial. All patients received intensive dietary counseling. Lovastatin or placebo was begun at 20 mg/d and was titrated to 40 and 80 mg during the first 16 weeks to attain a fasting low-density lipoprotein (LDL) cholesterol < or = 130 mg/dL. The mean lovastatin dose was 36 mg/d. Coronary arteriography was repeated after 2 years. In 299 patients (90%), 3858 coronary segments containing 2309 stenoses were measured blindly on pairs of films with an automated computerized quantitative system. Total and LDL cholesterol decreased by 21 +/- 11% and 29 +/- 11%, respectively, in the lovastatin-treated group but changed by < 2% in placebo patients. The primary end point, coronary change score, defined as the per-patient mean of the minimum lumen diameter changes (follow-up minus baseline angiogram) for all lesions measured, excluding those < 25% on both films, worsened by 0.09 +/- 0.16 mm in the placebo group and by 0.05 +/- 0.13 mm in the lovastatin group (P = .01). Progression (a worsening in minimum diameter of one or more stenoses by > or = 0.4 mm) with no regression at other sites occurred in 48 of 146 lovastatin and 76 of 153 placebo patients (33% versus 50%, P = .003). New coronary lesions developed in 23 lovastatin and 49 placebo patients (P = .001). The beneficial effect of treatment was most pronounced in the more numerous, milder lesions and in patients whose baseline total or LDL cholesterol levels were above the group median. CONCLUSIONS: Lovastatin slows the progression of coronary atherosclerosis and inhibits the development of new coronary lesions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Goodman, D. S. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.1988.00380010040006 · Cited by 2,246
Brown, G., Albers, J. J., Fisher, L. D., Schaefer, S. M., Lin, J.-T., Kaplan, C., Zhao, X.-Q., Bisson, B. D., Fitzpatrick, V. F., & Dodge, H. T. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011083231901 · Cited by 2,159
Blankenhorn, D. H. (1987) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1987.03390230069027 · Cited by 1,655
Buchwald, H., Varco, R. L., Matts, J. P., Long, J. M., Fitch, L. L., Campbell, G. S., Pearce, M. B., Yellin, A. E., Edmiston, W. A., Smink, R. D., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010043231404 · Cited by 1,001
Watts, G. F., Lewis, B., Lewis, E. S., Coltart, D. J., Smith, L. D. R., Swan, A. V., Brunt, J. N. H., & Mann, J. I. (1992) · The Lancet · doi:10.1016/0140-6736(92)90863-x · Cited by 843 · cited 1×
“The main exclusion criteria were (1) previous coronary bypass surgery; (2) coronary angioplasty in the 6 months preceding the qualifying coronary arteriogram; (3) ejection fraction <40%; (4) left main coronary artery stenosis >50%; (5) three-vessel disease with preseptal left anterior descending stenosis >70%; (6) any…”
BackgroundKane, J. P. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03450230043027 · Cited by 829
Blankenhorn, D. H., Azen, S. P., Kramsch, D. M., Mack, W. J., Cashin-Hemphill, L., Hodis, H. N., DeBoer, L. W. V., Mahrer, P. R., Masteller, M. J., Vailas, L. I., et al. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-10-199311150-00002 · Cited by 637
ARNETT, E. N., ISNER, J. M., REDWOOD, D. R., KENT, K. M., BAKER, W. P., ACKERSTEIN, H., & ROBERTS, W. C. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-3-350 · Cited by 628
Retardation of angiographic progression of coronary artery disease by nifedipine
Lichtlen, P. R., Rafflenbeul, W., Hecker, H., Jost, S., Hugenholtz, P. G., & Deckers, J. W. (1990) · The Lancet · doi:10.1016/0140-6736(90)91121-p · Cited by 611
Cited by
Nissen, S. E., Nicholls, S. J., Sipahi, I., Libby, P., Raichlen, J. S., Ballantyne, C. M., Davignon, J., Erbel, R., Fruchart, J. C., Tardif, J.-C., et al. (2006) · JAMA · doi:10.1001/jama.295.13.jpc60002 · Cited by 2,047
Thompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463
Effect of Statins on Risk of Coronary Disease: A Meta-analysis of Randomized Controlled Trials
LaRosa, J. C., He, J., & Vupputuri, S. (1999) · JAMA · doi:10.1001/jama.282.24.2340 · Cited by 1,246
Wood, D., De Backer, G., Faergeman, O., Graham, I., Mancia, G., & Pyörälä, K. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(98)90209-x · Cited by 1,255
Second Joint Task Force of European (1998) · European Heart Journal · doi:10.1053/euhj.1998.1243 · Cited by 1,131
(1997) · New England Journal of Medicine · doi:10.1056/nejm199701163360301 · Cited by 970
Greenland, P., Bonow, R. O., Brundage, B. H., Budoff, M. J., Eisenberg, M. J., Grundy, S. M., Lauer, M. S., Post, W. S., Raggi, P., Redberg, R. F., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.10.001 · Cited by 962
Antiatherothrombotic Properties of Statins: Implications for Cardiovascular Event Reduction
Rosenson, R. S., & Tangney, C. C. (1998) · JAMA · doi:10.1001/jama.279.20.1643 · Cited by 954
Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors
Tobert, J. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1112 · Cited by 875
Jukema, J. W., Bruschke, A. V. G., van Boven, A. J., Reiber, J. H. C., Bal, E. T., Zwinderman, A. H., Jansen, H., Boerma, G. J. M., van Rappard, F. M., & Lie, K. I. (1995) · Circulation · doi:10.1161/01.cir.91.10.2528 · Cited by 842
Hebert, P. R. (1997) · JAMA · doi:10.1001/jama.1997.03550040069040 · Cited by 740
Tardif, J.-C. (2007) · JAMA · doi:10.1001/jama.297.15.jpc70004 · Cited by 726
Callister, T. Q., Raggi, P., Cooil, B., Lippolis, N. J., & Russo, D. J. (1998) · New England Journal of Medicine · doi:10.1056/nejm199812313392703 · Cited by 682
Cholesterol Reduction in Cardiovascular Disease — Clinical Benefits and Possible Mechanisms
Levine, G. N., Keaney, J. F., & Vita, J. A. (1995) · New England Journal of Medicine · doi:10.1056/nejm199502233320807 · Cited by 672
Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS)
MAAS Investigators (1994) · The Lancet · doi:10.1016/s0140-6736(94)92082-6 · Cited by 647
Kuivenhoven, J. A., Jukema, J. W., Zwinderman, A. H., de Knijff, P., McPherson, R., Bruschke, A. V. G., Lie, K. I., & Kastelein, J. J. P. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801083380203 · Cited by 625
Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II)
Crouse, J. R., Byington, R. P., Bond, M. G., Espefand, M. A., Craven, T. E., Sprinkle, J. W., McGovern, M. E., & Furberg, C. D. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80580-3 · Cited by 609
Statins and Cancer Risk: A Meta-analysis
Dale, K. M., Coleman, C. I., Henyan, N. N., Kluger, J., & White, C. M. (2006) · JAMA · doi:10.1001/jama.295.1.74 · Cited by 599
The evolving role of statins in the management of atherosclerosis
Vaughan, C. J., Gotto, A. M., & Basson, C. T. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00525-2 · Cited by 574
von Schacky, C., Angerer, P., Kothny, W., Theisen, K., & Mudra, H. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-7-199904060-00003 · Cited by 487
Optimal low-density lipoprotein is 50 to 70 mg/dl
O'Keefe, J. H., Cordain, L., Harris, W. H., Moe, R. M., & Vogel, R. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.03.046 · Cited by 477
Cholesterol Reduction Yields Clinical Benefit: Impact of Statin Trials
Gould, A. L., Rossouw, J. E., Santanello, N. C., Heyse, J. F., & Furberg, C. D. (1998) · Circulation · doi:10.1161/01.cir.97.10.946 · Cited by 442
Lacoste, L., Lam, J. Y. T., Hung, J., Letchacovski, G., Solymoss, C. B., & Waters, D. (1995) · Circulation · doi:10.1161/01.cir.92.11.3172 · Cited by 441
Self-citationPitt, B., Mancini, G. B. J., Ellis, S. G., Rosman, H. S., Park, J.-S., & Mcgovern, M. E. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00301-0 · Cited by 429
Pleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction?
Robinson, J. G., Smith, B., Maheshwari, N., & Schrott, H. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.05.085 · Cited by 407
Frick, M. H., Syvänne, M., Nieminen, M. S., Kauma, H., Majahalme, S., Virtanen, V., Kesäniemi, Y. A., Pasternack, A., & Taskinen, M.-R. (1997) · Circulation · doi:10.1161/01.cir.96.7.2137 · Cited by 388
Schartl, M., Bocksch, W., Koschyk, D. H., Voelker, W., Karsch, K. R., Kreuzer, J., Hausmann, D., Beckmann, S., Gross, M., & for the German Atorvastatin Intravascular Ultrasound Study Investigators (GAIN) (2001) · Circulation · doi:10.1161/hc2901.093188 · Cited by 367
Colli, S., Eligini, S., Lalli, M., Camera, M., Paoletti, R., & Tremoli, E. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.2.265 · Cited by 348
Mills, E. J., WU, P., Chong, G., Ghement, I., Singh, S., Akl, E. A., Eyawo, O., Guyatt, G., Berwanger, O., & Briel, M. (2011) · QJM · doi:10.1093/qjmed/hcq165 · Cited by 338
Gould, K. L. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03530110056036 · Cited by 329
Herd, J. A., Ballantyne, C. M., Farmer, J. A., Ferguson, J. J., Jones, P. H., West, M. S., Gould, K. L., & Gotto, A. M. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00346-9 · Cited by 315
Lea, A. P., & McTavish, D. (1997) · Drugs · doi:10.2165/00003495-199753050-00011 · Cited by 290
Range of serum cholesterol values in the population developing coronary artery disease
Kannel, W. B. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80474-3 · Cited by 289
Lack of Effect of Lovastatin on Restenosis after Coronary Angioplasty
Weintraub, W. S., Boccuzzi, S. J., Klein, J. L., Kosinski, A. S., King, S. B., Ivanhoe, R., Cedarholm, J. C., Stillabower, M. E., Talley, J. D., DeMaio, S. J., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312002 · Cited by 289
Self-citationEffectiveness of Statin Therapy in Adults With Coronary Heart Disease
Wilt, T. J., Bloomfield, H. E., MacDonald, R., Nelson, D., Rutks, I., Ho, M., Larsen, G., McCall, A., Pineros, S., & Sales, A. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.13.1427 · Cited by 275
Pharmacology of competitive inhibitors of HMg-CoA reductase
Corsini, A. (1995) · Pharmacological Research · doi:10.1016/1043-6618(95)80042-5 · Cited by 277
Cholesterol Reduction Yields Clinical Benefit: A New Look at Old Data
Gould, A. L., Rossouw, J. E., Santanello, N. C., Heyse, J. F., & Furberg, C. D. (1995) · Circulation · doi:10.1161/01.cir.91.8.2274 · Cited by 272
Kroon, A. A., Aengevaeren, W. R. M., van der Werf, T., Uijen, G. J. H., Reiber, J. H. C., Bruschke, A. V. G., & Stalenhoef, A. F. H. (1996) · Circulation · doi:10.1161/01.cir.93.10.1826 · Cited by 275
Teo, K. K., Burton, J. R., Buller, C. E., Plante, S., Catellier, D., Tymchak, W., Dzavik, V., Taylor, D., Yokoyama, S., & Montague, T. J. (2000) · Circulation · doi:10.1161/01.cir.102.15.1748 · Cited by 275
Danaei, G., Tavakkoli, M., & Hernán, M. A. (2012) · American Journal of Epidemiology · doi:10.1093/aje/kwr301 · Cited by 264
de Groot, E., Jukema, J. W., Montauban van Swijndregt, A. D., Zwinderman, A. H., Ackerstaff, R. G. A., van der Steen, A. F. W., Bom, N., Lie, K. I., & Bruschke, A. V. G. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00170-3 · Cited by 258
Diagnosis and treatment of familial hypercholesterolaemia
Hovingh, G. K., Davidson, M. H., Kastelein, J. J. P., & O'Connor, A. M. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht015 · Cited by 256
MacMahon, S., Sharpe, N., Gamble, G., Hart, H., Scott, J., Simes, J., & White, H. (1998) · Circulation · doi:10.1161/01.cir.97.18.1784 · Cited by 254
A systematic review of statin-induced muscle problems in clinical trials
Ganga, H. V., Slim, H. B., & Thompson, P. D. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.03.019 · Cited by 253
Tardif, J.-C., Ballantyne, C. M., Barter, P., Dasseux, J.-L., Fayad, Z. A., Guertin, M.-C., Kastelein, J. J. P., Keyserling, C., Klepp, H., Koenig, W., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu171 · Cited by 251
Self-citationNovel HDL-directed pharmacotherapeutic strategies
deGoma, E. M., & Rader, D. J. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.200 · Cited by 149
The role of fibrates in managing hyperlipidemia: Mechanisms of action and clinical efficacy
Fazio, S., & Linton, M. F. (2004) · Current Atherosclerosis Reports · doi:10.1007/s11883-004-0104-8 · Cited by 118
The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk
Corsini, A. (2003) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1026132412074 · Cited by 82
Hsia, J., Bittner, V., Tripputi, M., & Howard, B. V. (2003) · American Heart Journal · doi:10.1016/s0002-8703(03)00227-8 · Cited by 43
Mellen, P. B., Cefalu, W. T., & Herrington, D. M. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000191656.71812.7c · Cited by 38
Metadata
- Authors
- Waters, D., Higginson, L., Gladstone, P., Kimball, B., Le May, M., Boccuzzi, S. J., & Lespérance, J.
- Venue
- Circulation
- Published
- 1994-03
- Volume
- 89
- Issue
- 3
- Pages
- 959-968
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2005786831
- Cited by
- 499
- References
- 20
- FWCI
- 61.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.